Jurg Oehen
Directeur/Membre du Conseil chez Celgene Europe Ltd.
Profil
Jurg Oehen is currently a Secretary & Director at Celgene UK Manufacturing (II) Ltd., Celgene UK Manufacturing Ltd., Celgene UK Holdings Ltd., and a Director at Celgene Europe Ltd.
Previously, he was a Chief Executive Officer at Delinia, Inc. and a Director at Celgene Ltd.
from 2006 to 2019.
Postes actifs de Jurg Oehen
| Sociétés | Poste | Début |
|---|---|---|
Celgene Europe Ltd.
 Celgene Europe Ltd. BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Celgene Europe Ltd. is a British company that engages in research and development in pharmaceutical products. The company is based in Middlesex, UK. | Directeur/Membre du Conseil | - |
Celgene UK Holdings Ltd.
 Celgene UK Holdings Ltd. Financial ConglomeratesFinance Part of Bristol Myers Squibb Co., Celgene UK Holdings Ltd. functions as an investment holding company. The company is based in London, UK. | Directeur/Membre du Conseil | - |
Celgene UK Manufacturing (II) Ltd.
 Celgene UK Manufacturing (II) Ltd. Financial ConglomeratesFinance Part of Bristol Myers Squibb Co., Celgene UK Manufacturing (II) Ltd. functions as an investment holding company. The company is based in London, UK. | Directeur/Membre du Conseil | - |
Celgene UK Manufacturing Ltd.
 Celgene UK Manufacturing Ltd. Financial ConglomeratesFinance Part of Bristol Myers Squibb Co., Celgene UK Manufacturing Ltd. functions as an investment holding company. The company is based in London, UK. | Directeur/Membre du Conseil | - |
Anciens postes connus de Jurg Oehen
| Sociétés | Poste | Fin |
|---|---|---|
Celgene Ltd.
 Celgene Ltd. Pharmaceuticals: MajorHealth Technology Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom. | Directeur/Membre du Conseil | 20/02/2019 |
Delinea, Inc. (United States)
 Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Celgene UK Manufacturing Ltd.
Celgene UK Manufacturing Ltd. Financial ConglomeratesFinance Part of Bristol Myers Squibb Co., Celgene UK Manufacturing Ltd. functions as an investment holding company. The company is based in London, UK. | Finance |
Celgene UK Holdings Ltd.
Celgene UK Holdings Ltd. Financial ConglomeratesFinance Part of Bristol Myers Squibb Co., Celgene UK Holdings Ltd. functions as an investment holding company. The company is based in London, UK. | Finance |
Celgene Ltd.
Celgene Ltd. Pharmaceuticals: MajorHealth Technology Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom. | Health Technology |
Delinea, Inc. (United States)
Delinea, Inc. (United States) BiotechnologyHealth Technology Delinia, Inc. operates as a biotechnology company that develops novel therapeutics for the treatment of autoimmune diseases. Its main program is a molecule that potentiates and expands Regulatory T Cells, powerful immune cells that are critical to maintaining self-tolerance and immune system homeostasis. Tregs are critically important immune regulatory cells in the path physiology of cancer and autoimmune disease. Delinia was founded by Michael Rosenblum and Jeffrey Greve in 2015 and is headquartered in Summit, NJ. | Health Technology |
Celgene Europe Ltd.
Celgene Europe Ltd. BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Celgene Europe Ltd. is a British company that engages in research and development in pharmaceutical products. The company is based in Middlesex, UK. | Health Technology |
Celgene UK Manufacturing (II) Ltd.
Celgene UK Manufacturing (II) Ltd. Financial ConglomeratesFinance Part of Bristol Myers Squibb Co., Celgene UK Manufacturing (II) Ltd. functions as an investment holding company. The company is based in London, UK. | Finance |
